Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PET findings safely drive chemo decisions in Hodgkin lymphoma patients

Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

Key clinical point: De-escalating chemotherapy based on PET findings significantly reduced certain toxicities without compromising efficacy in Hodgkin lymphoma patients.

Major finding: With a median follow-up of 50.4 months, progression-free survival was not significantly different for escalated BEACOPP vs. the experimental arm (HR, 1.084; 95% CI, 0.73-1.59; P = .68).

Study details: Final analysis of AHL2011 LYSA, a randomized phase 3 study including 823 patients with advanced-stage Hodgkin lymphoma.

Disclosures: Dr. Casasnovas reported financial ties to AbbVie, Bristol-Myers Squibb, Celgene, Gilead Sciences, Janssen, Merck, Roche/Genentech, Sanofi, and Takeda.

Source: Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

Read the article.

Citation:

Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

This Week's Must Reads

Gene therapy in severe hemophilia B, Reiss UM et al. ASH 2018, Abstract 491

Luspatercept reduced transfusion burden in trial, List AF et al. ASH 2018, abstract 1

Consider bleeding disorders in heavy menstrual bleeding, O’Brien B et al. J Pediatr Adolesc Gynecol. 2018 Nov 22 . doi: 10.1016/j.jpag.2018.11.005

Lower-dose treatment could save money in aTTP, Zwicker JI et al. ASH 2018, Abstract 374

Low rates of bleeding with DOAC interruption, Douketis J et al. ASH 2018, Abstract LBA-5

Must Reads in Aggressive Lymphomas

Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NH, Advani R et al. N Engl J Med. 2018;379:1711-21

Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025

Complications in EPOCH-R versus R-CHOP, David RJ et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 29. doi: 10.1016/j.clml.2018.08.014